Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00750256 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK1278863A in Healthy Subjects

A Phase 1 study of Anaemia, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 1
Development phase
36
Enrollment target
1
Study location

NCT00750256 is a Phase 1 study of Anaemia that has completed, run by GlaxoSmithKline. The registered enrollment target is 36 participants, below the 64-participant average among 3 other Anaemia trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00750256, a Phase 1 study of Anaemia, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 1
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

A first-time in human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK1278863A in healthy subjects

Conditions Studied

Interventions

  • DRUG GSK1278863A

Study Locations (1)

Indiana

  • GSK Investigational Site - Evansville

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2008-07-07
Est. Completion 2008-12-12
Phase Phase 1

Sponsor

GlaxoSmithKline

1,345 total trials

What the Registry Record Tells You About NCT00750256

The ClinicalTrials.gov registry entry for NCT00750256 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 64-participant average among 3 other Anaemia trials with a reported enrollment target (44% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Anaemia appearing as the primary indexed condition, and to 1 intervention - of which GSK1278863A is the first listed.

NCT00750256 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.

Frequently Asked Questions

What is clinical trial NCT00750256 about?

NCT00750256 is a clinical study titled "A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK1278863A in Healthy Subjects". A first-time in human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK1278863A in healthy subjects

What is the current status of trial NCT00750256?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2008-07-07. Estimated completion is 2008-12-12.

What conditions does trial NCT00750256 study?

This clinical trial studies the following conditions: Anaemia.

What interventions are being tested in trial NCT00750256?

The interventions under investigation include: GSK1278863A (DRUG).

Who is sponsoring clinical trial NCT00750256?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00750256 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anaemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.